AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21948951
Drug: Patient-controlled local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled local analgesia (PCLA): self‐administration of 10 ml of ropivacaine 2 mg ml⁻¹ via the intra‐abdominal catheter for 48 h.
Trial: 21948951
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA): infusion of 10 ml h⁻¹ of ropivacaine 1 mg ml⁻¹, fentanyl 2 μg ml⁻¹, and epinephrine 2 μg ml⁻¹ epidurally for 48 h.
Trial: 19430766
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of Kava (5 tablets per day containing 250 mg of kavalactones/day)
Trial: 1414179
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Trial: 1414179
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Trial: 27125818
Drug: SSRI prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI prescribing prior to psychological treatment
Trial: 17873306
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg three times a day orally) and alpha-tocopherol (300 mg twice a day orally) during radiotherapy, followed by 400 mg once a day and 300 mg once a day for 3 months after radiotherapy.
Trial: 10093981
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (intravenous methylprednisolone 1 g per day for 3 consecutive days at the beginning of months 1, 3, and 5, plus oral prednisone 0.5 mg/kg on alternate days for 6 months)
Trial: 17611080
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy alone
Trial: 2257861
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A once daily in the evening
Trial: 2257861
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A b.d.
Trial: 2257861
Drug: Drug B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug B b.d.
Trial: 2257861
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A b.d. and Drug B b.d.
Trial: 25560201
Drug: Fluoxetine (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (selective serotonin reuptake inhibitor) for 3 weeks
Trial: 18373121
Drug: 2 cc
RxNorm normalized name: Bag Reclosable 2 cc 2X8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cc of fibrin glue intraoperatively
Trial: 14750421
Drug: Hydacorn (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydacorn (1 mg dihydroergotamine, 40 mg caffeine, 100 mg diphenylhydantoine)
Trial: 8238826
Drug: Fentanyl/bupivacaine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl/bupivacaine (2.5 micrograms.ml‐1 of fentanyl)
Trial: 8238826
Drug: Sufentanil/bupivacaine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil/bupivacaine (0.25 micrograms.ml‐1 of sufentanil)
Trial: 27491663
Drug: Electronically delivered,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronically delivered, multicomponent interventions including feedback of antibiotic prescribing reports, educational tools, and a webinar for 12 months.
Trial: 11605101
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg alcohol
Trial: 7862844
Drug: 0.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 g/kg alcohol
Trial: 20838118
Drug: rFVIIa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (200 μg/kg initially; 100 μg/kg at 1 hour and 3 hours)
Trial: 21689411
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg/day
Trial: 8728351
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg for days 1-3, 20 mg for days 4-14)
Trial: 1906716
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate inhalation aerosol preparation 1
Trial: 1906716
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate inhalation aerosol preparation 2
Trial: 28614197
Drug: Randomized Evaluation
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Trial: 28614197
Drug: Extracorporeal membrane
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal membrane oxygenation patients managed per Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Trial: 22685670
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (400 mg) until delivery
Trial: 17258626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium hydroxide and chlorhexidine [Ca(OH)2/CHX]
Trial: 16322398
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (BIAsp30) administered via multiple daily injections for 12 weeks
Trial: 9637640
Drug: Lateral approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Trial: 9637640
Drug: Posterior approach
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Trial: 2973269
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide inhaled as a dry powder (40 micrograms)
Trial: 28244205
Drug: Sacubitril-valsartan eligibility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril-valsartan eligibility criteria applied to patients on target doses of ACE inhibitors or ARBs
Trial: 28244205
Drug: Sacubitril-valsartan eligibility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril-valsartan eligibility criteria applied to all patients regardless of background medication
Trial: 28244205
Drug: Sacubitril-valsartan eligibility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril-valsartan eligibility criteria applied ignoring background medication
Trial: 25819691
Drug: Oral eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral eliglustat
Trial: 23894336
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (risperidone and aripiprazole)
Trial: 21199699
Drug: 2009 A/H1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered simultaneously with seasonal virosomal‐adjuvanted influenza vaccine
Trial: 21199699
Drug: 2009 A/H1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered sequentially with seasonal virosomal‐adjuvanted influenza vaccine
Trial: 21199699
Drug: Seasonal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal vaccine administered alone
Trial: 21199699
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of pandemic and seasonal vaccines
Trial: 11600556
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg) premeal (‐10,‐1 min)
Trial: 11600556
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg) postmeal (+10 min)
Trial: 11600556
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg) before meals (10 min before)
Trial: 11600556
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg) after meals (10 min after)
Trial: 7981071
Drug: OND/MPD (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OND/MPD (8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed by 8 mg OND tablet and 16 mg MPD tablet orally for 3-5 days)
Trial: 7981071
Drug: OND (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OND (8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8 mg OND tablet and placebo orally for 3-5 days)
Trial: 30610502
Drug: Combined chitosan
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chitosan and Dan-shen injection
Trial: 16919531
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg/d, 12 weeks)
Trial: 11371410
Drug: Heat-killed Mycobacterium
RxNorm normalized name: Mycobacterium phlei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Mycobacterium vaccae (0.5 mg)
Trial: 11371410
Drug: Delipidated deglycolipidated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delipidated deglycolipidated Mycobacterium vaccae (DDMV) (0.05 mg)
Trial: 31364105
Drug: Vaginal Soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Soft gels technology
Trial: 28850362
Drug: Oxycodone 15mg
RxNorm normalized name: oxycodone hydrochloride 15 MG [Roxicodone]
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 15mg
Trial: 26083699
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) instructed not to change daily routines and not allowed to ski
Trial: 18326964
Drug: Low-dose diuretic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose diuretic
Trial: 12747879
Drug: ICL670 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICL670 at 10 mg x kg(‐1) x day(‐1)
Trial: 12747879
Drug: ICL670 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICL670 at 20 mg x kg(‐1) x day(‐1)
Trial: 12747879
Drug: ICL670 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICL670 at 40 mg x kg(‐1) x day(‐1)
Trial: 6397330
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide plus 50 mg triamterene
Trial: 2897305
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide plus 5 mg amiloride
Trial: 26051494
Drug: Inositol-enriched beverage
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol-enriched beverage (IEB) containing 2.23 g of inositols in 250 ml
Trial: 25456755
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day atorvastatin
Trial: 20830491
Drug: Midazolam group
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam group (50 μg/kg midazolam added to 3 mg/kg lidocaine 2% w/v)
Trial: 20830491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3 mg/kg lidocaine 2% w/v diluted with saline to 40 ml)
Trial: 12479119
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone
Trial: 12479119
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment + Viagra
Trial: 9656089
Drug: Computer-administered rating
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-administered rating scales (LSAS, BSPS, Fear Questionnaire)
Trial: 9656089
Drug: Computer-administered rating
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-administered rating scales
Trial: 27654852
Drug: PR1 peptide
RxNorm normalized name: PROTEINASE 3 PR1 PEPTIDE
DrugBank: PR1 leukemia peptide vaccine (DB15276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR1 peptide vaccine (0.25, 0.5 or 1.0 mg, administered subcutaneously every 3 weeks)
Trial: 27654852
Drug: PR1 peptide
RxNorm normalized name: PROTEINASE 3 PR1 PEPTIDE
DrugBank: PR1 leukemia peptide vaccine (DB15276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR1 peptide vaccine
Trial: 20128231
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with monomeric allergoid at a dosage of 1000 AU five times a week for two years
Trial: 26875905
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug therapy)
Trial: 1388220
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined oestradiol valerate/cyproterone acetate (2 mg E2V + 1 mg CPA daily)
Trial: 3895386
Drug: Psychotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy combined with medical treatment for IBS
Trial: 3895386
Drug: Psychotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy combined with medical treatment for PUD
Trial: 3895386
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only for IBS
Trial: 3895386
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only for PUD
Trial: 25659440
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administration: bolus dose of 15 mg/kg 10 min before tourniquet inflation, intra-articular administration of 3 grams 10 min before tourniquet deflation, IV infusion of 10 mg/kg/h for 3 h after completion on the second side.
Trial: 25058218
Drug: Everolimus, 7.5
RxNorm normalized name: Everolimus, 7.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus, 7.5 mg/d
Trial: 22334770
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Trial: 22334769
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Trial: 19243713
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/d for 8 weeks
Trial: 19243713
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/d for 8 weeks (subgroup of clinically responsive patients)
Trial: 17435976
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of ACEI therapy (premed group)
Trial: 17435976
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of ACEI therapy (withdrawal group)
Trial: 15385353
Drug: Standard propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard propofol LCT with 20 mg lidocaine (group L; n = 113)
Trial: 15385353
Drug: Standard propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard propofol LCT with 20 mg lidocaine (group L)
Trial: 11238801
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (AGE) at doses between 2.4 and 7.2 g/d
Trial: 11238801
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (AGE) at 7.2 g/d
Trial: 7639417
Drug: L-propionylcarnitine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionylcarnitine (300 mg)
Trial: 7639417
Drug: L-propionylcarnitine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionylcarnitine (600 mg)
Trial: 7639417
Drug: L-propionylcarnitine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionylcarnitine (1200 mg)
Trial: 2502040
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (TRH) 20 mg p.o. (five doses during 30 hr preceding ethanol intake)
Trial: 2502040
Drug: Ethanol 1
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 1 g/kg p.o. during 1 hr
Trial: 31535460
Drug: l-arginine (ARG:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (ARG: 3.2 g)
Trial: 31535460
Drug: wheat protein
RxNorm normalized name: Wheat protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wheat protein hydrolysate (WPH: 2 g) + l-arginine (ARG: 3.2 g)
Trial: 15001607
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone enanthate (1 mg/kg) and letrozole (2.5 mg orally once a day for 0-12 months)
Trial: 11396248
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (SH) 2 x 7500 U s.c.
Trial: 11396248
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) Dalteparin 1 x 5000 anti-Xa U s.c. once daily.
Trial: 30633660
Drug: Glycine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (0.8 g/kg weekly for 12 weeks)
Trial: 30633660
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching to glycine, provided in bottles with mixed in solution)
Trial: 27077672
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rosiglitazone and rhGH
Trial: 25051839
Drug: Silibinin combined
RxNorm normalized name: Silibinin
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silibinin combined with Ruangan pills
Trial: 22270273
Drug: Lubricating gel
RxNorm normalized name: Via Moisturizer For Her Lubricating Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricating gel (0.3 mL)
Trial: 22270273
Drug: Water (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (3 mL)
Trial: 19241078
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus 500 mg zosuquidar.3HCl (DZ)
Trial: 21352110
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) for 12 months
Trial: 15187819
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (2 g orally in effervescent tablets)
Trial: 15187819
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral in effervescent tablets)
Trial: 10789607
Drug: Perceived treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived treatment improvement
Trial: 8902254
Drug: Magnesium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (10 mmol twice-daily)
Trial: 1862029
Drug: 10% sulfur
RxNorm normalized name: SULFUR 10 g in 100 g TOPICAL SOAP [Dermaharmony 10% Sulfur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sulfur in cold cream
Trial: 6140811
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol (40 mg X 2)
Trial: 19700442
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg i.v.
Trial: 19945275
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg i.v.
Trial: 16234833
Drug: Supplemented with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented with high-energy, nutrient dense food from 4 to 7 months of age, twice daily under supervision of field workers.
Trial: 10755105
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% twice daily added to timolol maleate 0.5% twice daily